Lyell Immunopharma, Inc. Common Stock (LYEL)

Price$12.57

Value ScoreD

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-48.05%

Price vs S&P 500 (4W)-32.73%

VGM Score28.90

Market Capitalization$347.44M

All Metrics

Book Value / Share (Quarterly)$11.73

P/TBV (Annual)0.51x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-92.48%

Cash Flow / Share (Quarterly)$-7.53

Price vs S&P 500 (YTD)-63.01%

Net Profit Margin (TTM)-794858.06%

EPS (TTM)$-12.98

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-12.98

Revenue Growth (5Y)-65.86%

EPS (Annual)$-16.06

ROI (Annual)-110.57%

Net Profit Margin (5Y Avg)-301538.54%

Cash / Share (Quarterly)$10.89

Revenue Growth QoQ (YoY)-71.43%

ROA (Last FY)-80.71%

Revenue Growth TTM (YoY)-52.31%

EBITD / Share (TTM)$-12.98

ROE (5Y Avg)-56.98%

Operating Margin (TTM)-823341.94%

Cash Flow / Share (Annual)$-9.03

P/B Ratio1.27x

P/B Ratio (Quarterly)1.71x

Net Income / Employee (Annual)$-1,704,600

EV / Revenue (TTM)8279.83x

ROA (TTM)-66.41%

EPS Incl Extra (Annual)$-16.06

Current Ratio (Annual)5.28x

Quick Ratio (Quarterly)6.88x

3-Month Avg Trading Volume0.09M

52-Week Price Return81.14%

Revenue / Employee (TTM)$200

Tangible BV / Share (Quarterly)$2.77

P/S Ratio (Annual)9651.24x

Asset Turnover (Annual)0.00x

52-Week High$45.00

Operating Margin (5Y Avg)-312062.62%

EPS Excl Extra (Annual)$-16.06

CapEx CAGR (5Y)-4.00%

26-Week Price Return-34.46%

Quick Ratio (Annual)5.00x

13-Week Price Return-38.22%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.23x

Enterprise Value$256.67M

Revenue / Share Growth (5Y)-42.00%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$200

Pretax Margin (Annual)-762355.56%

Cash / Share (Annual)$11.63

3-Month Return Std Dev74.85%

Net Income / Employee (TTM)$-1,530,500

ROE (Last FY)-110.57%

EPS Basic Excl Extra (Annual)$-16.06

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-12.98

ROI (TTM)-85.71%

P/S Ratio (TTM)11207.90x

Pretax Margin (5Y Avg)-301538.54%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.34

Price vs S&P 500 (52W)52.99%

Year-to-Date Return-51.62%

5-Day Price Return-11.00%

EPS Normalized (Annual)$-16.06

ROA (5Y Avg)-44.72%

Net Profit Margin (Annual)-762355.56%

Month-to-Date Return-14.08%

Cash Flow / Share (TTM)$-0.67

EBITD / Share (Annual)$-15.09

Operating Margin (Annual)-748344.44%

ROI (5Y Avg)-56.98%

EPS Basic Excl Extra (TTM)$-12.98

P/TBV (Quarterly)0.61x

P/B Ratio (Annual)2.63x

Pretax Margin (TTM)-794858.06%

Book Value / Share (Annual)$11.68

Price vs S&P 500 (13W)-48.88%

Beta-0.06x

P/FCF (Annual)14.84x

Revenue / Share (TTM)$0.00

ROE (TTM)-85.71%

52-Week Low$7.65

vGradeD

gGradeF

mGradeC

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-1.10est. -2.41

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.89

3.90

3.91

4.00

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
LYELLyell Immunopharma, Inc. Common Stock	D	F	C	$12.57
LLYEli Lilly & Co.	D	B	B	$1078.78
JNJJohnson & Johnson	C	C	C	$223.24
ABBVABBVIE INC.	D	C	C	$217.13
MRKMerck & Co., Inc.	C	C	C	$114.70
AZNAstraZeneca PLC	D	B	C	$176.28
NVSNovartis AG	C	C	C	$143.66
NVONovo-Nordisk A/S	B	B	B	$42.00
ABTAbbott Laboratories	C	C	D	$86.99
PFEPfizer Inc.	B	C	C	$25.34
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$32.83

About

Lyell Immunopharma is a clinical-stage cell therapy company developing T-cell therapies for solid tumors through proprietary ex vivo genetic and epigenetic reprogramming technology. The company's pipeline includes three lead candidates: LYL797, LYL119, and LYL845.